Umberto Pensato։ Left Ventricular Dysfunction and DOAC Benefit in ESUS
Umberto Pensato, Assistant Professor of Neurology at the Humanitas University, Research Collaborator at the University of Calgary, shared on X about a recent article by Richa Sharma et al., published in Stroke, adding:
”Super important ARCADIA post hoc!
LV dysfunction is a treatment effect modifier of DOACs for stroke prevention.
(ie DOAC benefits only in ESUS with LV dysfunction).”
Title: Apixaban and Recurrent Stroke Risk With Left Ventricular Dysfunction: A Secondary Analysis of the ARCADIA Trial
Authors: Richa Sharma, Dinesh Jillella, Cenai Zhang, Mitchell S.V. Elkind, Hooman Kamel, Marco R. Di Tullio, Richard A. Kronmal, Balaji Krishnaiah, Shadi Yaghi, W.T. Longstreth Jr, David L. Tirschwell, Alexander E. Merkler, Fadi Nahab
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 14, 2026, 15:22Meral Kayikcioglu: Why Do Women and Men Differ in LDL-C Management?
-
Sep 14, 2026, 15:22James Crowley: The Complex Role of CRP in Cardiovascular Risk and Atherosclerosis
-
Sep 14, 2026, 15:16Factor XIII Deficiency An Often-Missed Bleeding Disorder
-
Sep 14, 2026, 15:07Raffaele Piccolo: Heparin Against Jellyfish Venom?
-
Sep 14, 2026, 15:06Contemporary Research in Thrombosis and Hemostasis – Seminars in Thrombosis and Hemostasis
-
Sep 14, 2026, 15:00Obi Light Ogbonnia: Improving Outcomes for People Living with Sickle Cell Disease in Nigeria
-
Sep 14, 2026, 14:57Closing the Global Gap in NCD Prevention and Care – ISTH
-
Sep 14, 2026, 14:54Petter Brodin: A New Axis of Functional Variation in Human Immune Cells
-
Sep 14, 2026, 14:50Michael Meneghini: The Metabolic Picture Behind Cardiovascular Risk